B. Riley Financial Cuts OptimizeRx (NASDAQ:OPRX) Price Target to $10.00

OptimizeRx (NASDAQ:OPRX) had its price objective decreased by B. Riley Financial from $11.00 to $10.00 in a research report report published on Wednesday,Benzinga reports. B. Riley Financial currently has a buy rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Zacks Research cut shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 4th. UBS Group set a $10.00 price target on OptimizeRx in a research note on Wednesday. Lake Street Capital dropped their price target on OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday. Stephens dropped their price target on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a research note on Wednesday. Finally, Stifel Nicolaus dropped their price target on OptimizeRx from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, OptimizeRx currently has an average rating of “Moderate Buy” and an average price target of $13.43.

OptimizeRx Price Performance

NASDAQ:OPRX opened at $5.21 on Wednesday. OptimizeRx has a 1-year low of $4.57 and a 1-year high of $22.25. The company has a current ratio of 5.37, a quick ratio of 3.04 and a debt-to-equity ratio of 0.16. The firm has a fifty day simple moving average of $6.44 and a 200 day simple moving average of $10.68. The stock has a market capitalization of $97.74 million, a PE ratio of 14.89 and a beta of 1.19.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%. The business had revenue of $19.84 million during the quarter, compared to analysts’ expectations of $18.74 million. On average, research analysts expect that OptimizeRx will post 0.5 EPS for the current fiscal year.

OptimizeRx declared that its board has initiated a stock buyback plan on Thursday, March 5th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Institutional Trading of OptimizeRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OPRX. Rhumbline Advisers increased its position in OptimizeRx by 29.9% during the 2nd quarter. Rhumbline Advisers now owns 36,082 shares of the company’s stock valued at $487,000 after purchasing an additional 8,297 shares during the period. American Century Companies Inc. increased its position in OptimizeRx by 52.5% during the 2nd quarter. American Century Companies Inc. now owns 24,069 shares of the company’s stock valued at $325,000 after purchasing an additional 8,286 shares during the period. Russell Investments Group Ltd. increased its position in OptimizeRx by 141.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 110,610 shares of the company’s stock valued at $1,493,000 after purchasing an additional 64,790 shares during the period. Quantbot Technologies LP acquired a new stake in OptimizeRx during the 2nd quarter valued at approximately $44,000. Finally, WINTON GROUP Ltd acquired a new stake in OptimizeRx during the 2nd quarter valued at approximately $286,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.